New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 11, 2014
09:08 EDTICPTIntercept announces OCA preclinical study data
Intercept announced results from a preclinical study demonstrating the potential protective effects of obeticholic acid, or OCA, in an experimental model of liver disease. The study was presented orally during the opening session of the International Liver Congress 2014, the 49th Annual Meeting of the European Association for the Study of the Liver. The study has also been selected as the best oral abstract in Basic Science at ILC 2014. In the study, OCA administration was shown to have protective effects on bacterial translocation from the ileum in an experimental rat model of cholestasis. The six animals receiving OCA treatment experienced significant reduction of bacteria in mesenteric lymph nodes and all but one of these remained free from bacterial infection in the abdominal cavity. In contrast, all six animals in the control group developed an abdominal infection. OCA treatment was additionally associated with normalized intestinal permeability, along with reduced inflammation of the lymph nodes and spleen. This study is the first to show OCA treatment limits bacterial translocation from the small intestine. In patients with liver cirrhosis, this manifests as spontaneous bacterial peritonitis.
News For ICPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 4, 2015
16:34 EDTICPTShareholder suit against Intercept allowed to proceed, Reuters reports
Subscribe for More Information
15:52 EDTICPTShareholder suit against Intercept allowed to proceed, Reuters reports
11:09 EDTICPTSanofi, Novartis, Shire may be weighing Genfit acquisition, Bloomberg says
Subscribe for More Information
March 3, 2015
07:35 EDTICPTIntercept risk/reward positive, says RBC Capital
RBC Capital believes that Intercept will rally 20% or more if GenFit data, expected to be announced in the second half of March, isn't clean. If the GenFit data is positive, Intercept's stock might drop, but it would probably rebound, since the company would probably reach a deal with the FDA on a Phase III trial of its OCA drug soon thereafter, according to the firm. RBC keeps a $490 price target and Outperform rating on Intercept.
March 2, 2015
06:13 EDTICPTIntercept reports Q4 EPS ($1.63), consensus ($1.67)
Subscribe for More Information
February 19, 2015
16:31 EDTICPTIntercept promotes Lisa Bright to Chief Commercial & Corporate Affairs Officer
Intercept Pharmaceuticals announced that Lisa Bright has been promoted to the newly-created position of Chief Commercial and Corporate Affairs Officer. Bright joined Intercept last year from Gilead Sciences where her leadership of the European launch of Sovaldi for the treatment of chronic hepatitis C contributed to the most successful product launch in pharmaceutical history.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use